Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMI with Fludarabine and Busulfan for Allogeneic HPCT
NCT02129582Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2014
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in hematologic malignancy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 8 more, sponsored by Case Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose of Targeted Marrow Irradiation at Day 32. Started Nov 2014; status: completed.
02
Conditions
hematologic malignancyacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02129582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129582.